[1] Shetty B V, Rochester N Y, Belleville N J. Tetrahydro-halosulfamyl-quinazolinones[P]. US: 3 360 518,1967-12-26.
[2] Shetty B V, Rochester N Y. N and N, N-alkyl, acyl and aryl-sulfamyl-tetrahydroquinazones[P]. US: 3 557 111,1971-01-19.
[3] Shetty B V, Campanella L A, Thomas T L, et al. Synthesis and activity of some 3-aryl and 3-aralkyl-1,2,3,4-tetrahydyo-4-oxo-6-quinazolinesulfonamides[J]. J Med Chem,1970,13:886-895.
[4] Belair E J, Kaiser F, Van Denburgh B, et al. Pharmacology of SR 72022[J]. Arch Int Pharmacodyn Ther, 1969,177:71-87.
[5] Belair E J. The renal pharmacology of metolazone, 2-methyl-3-O-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone[J]. Res Comm Chem Pathol Pharmacol, 1971,2(1): 98-117.
[6] Schoonees R, Mostert J W, Moore R H. Evaluation of metolazone. New diuretic in chronic renal disease[J]. New York State Journal of Medicine, 1971,71:566-569 .
[7] Shetty B V. A review on a quinozolone diuretic zaroxolyn (metolazone) [J]. Ind J Pharmac, 1974,6(1):40-53.
[8] Materson B J, Oster J R, Perez-Stable E C. Antihypertensive effects of metolazone (zaroxolyn)[J]. Curr Ther Res Clin Exp,1974,16(9): 890-896.
[9] Leyey B-A, Palmer R F. Biochemical and clinical effects of metolazone in congestive heart failure[J]. Curr Ther Res Clin Exp,1975,18(5):641-651.
[10] Curry C L, Janda S M, Harris R, et al. Clinical studies of a new, low-dose formulation of metolazone for the treatment of hypertension[J]. Clin Ther, 1986,9(1):47-62.
[11] Kinyingi A, Field M J, Pawsey C C, et al. Metolazone in treatment of severe refractory congestive cardiac failure[J]. Lancet,1990,335(8680):29-31.
[12] Sica D A. Pharmacotherapy in congestive heart failure: Metolazone and its role in edema management[J]. Congest Heart Fail, 2003,9(2):100-5. |